BioSpace News Archive

Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced its plan to develop a test to potentially triage COVID-19 patients into those likely versus unlikely to progress to severe respiratory failure.

With strong momentum in its growing portfolio of life science companies, Paragon Biosciences announced the appointment of Kerensa Jimenez as the new chief executive officer of its capital markets group, Paragon Health Capital (PHC), a registered broker-dealer.

PDL BioPharma, Inc. (“PDL” or the “Company”) (Nasdaq: PDLI) announces it has entered into a settlement agreement (the “Settlement Agreement”) with related entities of Defined Diagnostics, LLC (f/k/a Wellstat Diagnostics, LLC) (“Wellstat Diagnostics” and, together with such related entities, the “Wellstat Parties”) r

Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported financial results for the second quarter ended June 30, 2020 and provided an update on business progress.

Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense announced today the Clinical Trial Application (CTA) approval in the Netherlands for initiation of a first in-human clinical trial of KCP506.

Inteliquet, a leading provider of intelligent technology, insights, and services for optimizing clinical trials and research, announced today that it has hired Jean Roberson, CPA, as Chief Financial Officer (CFO).

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Karen Dahut to its Board of Directors, effective immediately.

MANA RBM and CUSP announce the randomization of the first subject in ESCALATE, A Phase III Randomized Study Comparing Enzalutamide or Darolutamide with Radium-223 vs Enzalutamide or Darolutamide with Placebo and the Effect upon Symptomatic Skeletal Event-Free Survival for mCRPC Patients, clinicaltrials.gov #NCT04237584].

Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing CAR NK cell therapy and NK engager antibodies for cancer, announced today that it has licensed from ProteoNic BV its 2G UNic™ technology for boosting recombinant protein production, allowing for cost-effective manufacturing at large scale

Mylan N.V. (NASDAQ: MYL) and Sesame Workshop, the non-profit educational organization behind Sesame Street, today announced a new effort to help children and families cope with the ongoing transitions and uncertainty stemming from the COVID-19 pandemic.